Precision Medicine Takes a Different Path From The GLP-1 Rush

CEO and Co-Founder Christian Stella says the company is focusing on a more deliberate approach to the longevity market and moving away from the crowded GLP-1 telehealth industry.

One of the most common reasons people seek telehealth consultations is for GLP-1 medications. These medications have become a widely sought-after part of weight management and longevity services. Their popularity resulted in a shortage of branded drugs, which led many telehealth companies to focus on offering compounded semaglutide and tirzepatide.

A specialized pharmacy prepares a compounded medication to fill a doctor’s prescription. Compounded GLP-1s were issued during the shortage to fill the gap, but once the shortage was resolved, regulations for compounded versions became more restrictive.

After these regulatory changes, companies built around GLP-1 access faced greater scrutiny. In this environment, Precision Medicine made a conscious decision to leave the competitive market centered on compounded GLP-1 medications and focus on medication categories it can support over the long term.

Precision Medicine Makes a Deliberate Exit

Precision Medicine took a different approach to its telehealth platform. On April 22, 2025, the company stopped compounding all GLP-1 formulations once the shortages of semaglutide and tirzepatide were resolved.

Photo Credit: Adobe Stock

This shift away from GLP-1 medications and the change in its product line was part of the company’s compliance-oriented strategy to compete in a swiftly evolving healthcare market. The goal is not to be the first to embrace the latest, biggest trend, but to create consistency around access, compliance, and continuity in products and service.

CEO and co-founder of Precision, Christian Stella, wanted to prioritize building an operation that was not only capable of reliably serving patients, but would also build durable treatment categories. These changes are meant to build a sustainable foundation for the company.

Sermorelin Gives the Company a Different Foundation

Precision Medicine is now concentrating on Sermorelin as part of the company’s focus on the longevity market.

Sermorelin is a laboratory-made version of a natural hormone signal called GHRH (Growth Hormone-Releasing Hormone). The body naturally produces this hormone, and its purpose is to tell the pituitary gland to release growth hormone, which helps regulate growth, metabolism, and the maintenance of body tissues,

Unlike the shortage-related circumstances that surrounded GLP-1 medications, Sermorelin has a history of being compounded and has regulatory and operational continuity. For this reason, Sermorelin has become one of Precision Medicine’s core initiatives.

Building Scale in a Quieter Category

According to Stella, the company is currently the number one supplier in the United States for NAD+ injection and sermorelin injection, proving that the move away from GLP-1 injections to hormone health and longevity was beneficial.

Stella believes that centering the company on compliance over speed, dependable access over short-term market demand, and durable treatment categories over temporary opportunities will result in an operation that continues to provide consistent support to providers and patients.

Under Stella’s leadership, Precision Medicine is building infrastructure around healthcare categories that he believes have staying power and aren’t dependent on a temporary shortage.

Disclaimer: Written in partnership with APG.